Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.
about
Current targeted therapies in the treatment of advanced colorectal cancer: a reviewEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsAngiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Colonic perforation with intraluminal stents and bevacizumab in advanced colorectal cancer: retrospective case series and literature reviewSafety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.Anti-VEGF Cancer Therapy in Nephrology PracticeTargeted therapies for gastric cancer: current status.Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis.Comparative effectiveness of anti-VEGF agents for diabetic macular edema.Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targetsThe VEGF pathway in cancer and disease: responses, resistance, and the path forward.Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression.Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.Ramucirumab for the treatment of gastroesophageal cancers.Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma.Investigational VEGF antagonists for psoriasis.Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.Bevacizumab in endometrial cancer treatment.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report.Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumabRecurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
P2860
Q26740067-233802A3-57D5-4927-9738-9150E7B009B4Q26786618-0C672065-199A-40F2-BEFD-3E9B8FD7B1B1Q27002538-2935DE3E-6021-4222-97C5-CA5EDD7A67F1Q27014015-B197C233-08AD-4CF4-8A44-554F5F185BD7Q31127134-A7EF4677-D966-4CA4-8064-5B39D93AE703Q31152878-A9ADD2D7-45FD-43E3-9DC7-6041C65B1E26Q33424566-AA887D74-1D7F-496F-804D-1F2AE3C29318Q34152125-D7350D06-4F01-41E3-B8D4-331AECF6A263Q34205672-EE07D9AC-EE95-48C0-A32C-9FE409FD1908Q34421695-93AE7DFA-17A1-456F-B235-C94A26B31D68Q35056819-69AAE84B-3621-4D8F-8A0A-4CC72F3556FDQ36158922-293B5FF6-4710-4FB4-AAF8-68DD074CE372Q36526512-C4934BEE-E53E-41E0-B3BC-0F620C92C821Q36729895-93CF5CC1-A5BE-4AF3-A89B-81138B1389EAQ36751861-F90DA0F2-B1F7-4422-A16C-9C62A9E2D396Q36831607-9BDEE51D-2A7B-4D86-BAC4-53C753D56FC2Q37102447-1A84048C-E45B-405B-8353-EB2166809B96Q37211153-0919CBB3-1D20-42F3-A4D0-CFAA50FB99B1Q37501114-A99AA765-CA74-48E0-89D6-5B39CC031F70Q37956733-32929DDC-B684-4C0A-AD5A-43B8EC36BF97Q37963823-B66FF75A-F840-4318-9AA6-F9B927F55D0AQ37994752-2E7BEAA5-3A33-4B8A-A890-ECFBA51D2973Q39282981-87CEFFBD-F3E5-413B-97DF-3E3AB2DBE01DQ43497234-73B38053-AEFC-4FAA-9B08-963C28873677Q48187031-0C95205B-7E2C-4DA7-BDB6-F779F91B239BQ54459895-DF54E66C-442C-484C-B822-274432EF4CBAQ58130125-332A7E14-A6D9-4BF6-BD25-227221A680DAQ58705919-0EE81E47-B951-4ED1-AAB1-599F13033E0F
P2860
Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety of bevacizumab in patie ...... randomized controlled trials.
@ast
Safety of bevacizumab in patie ...... randomized controlled trials.
@en
type
label
Safety of bevacizumab in patie ...... randomized controlled trials.
@ast
Safety of bevacizumab in patie ...... randomized controlled trials.
@en
prefLabel
Safety of bevacizumab in patie ...... randomized controlled trials.
@ast
Safety of bevacizumab in patie ...... randomized controlled trials.
@en
P2093
P2860
P50
P1433
P1476
Safety of bevacizumab in patie ...... f randomized controlled trials
@en
P2093
Beate Guba
Claudia Wild
Sabine Geiger-Gritsch
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0155
P577
2010-11-02T00:00:00Z